XNAS · Healthcare · Biotechnology
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | Q1 2026 | -0.49 | -0.33 | +32.65% | $0 | ✅ Beat | +0.00% | -12.50% | — |
| 2026-03-26 | Q4 2025 | -0.53 | -0.41 | +22.64% | $0 | ✅ Beat | +1.14% | +5.88% | +0.78% |
| 2025-11-12 |
| Q3 2025 |
| -0.66 |
| -0.44 |
| +33.33% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-12 | Q2 2025 | -0.53 | -0.68 | -28.30% | $0 | ❌ Miss | +4.23% | +9.52% | +10.32% |
| 2025-03-27 | Q4 2024 | -0.37 | -0.62 | -67.57% | $0 | ❌ Miss | -3.25% | -19.67% | -16.26% |
| 2024-08-13 | Q2 2024 | -0.28 | -0.34 | -21.43% | $0 | ❌ Miss | -9.21% | +2.17% | -11.55% |
| 2024-05-14 | Q1 2024 | -0.26 | -0.25 | +3.85% | $0 | ✅ Beat | +2.98% | +3.25% | -28.46% |
| 2024-03-26 | Q4 2023 | -0.26 | -0.29 | -11.54% | $0 | ❌ Miss | — | — | — |
Showing last 8 quarters.